Impact of Contrast-Induced Nephropathy and Cardiovascular Events by Serum Cystatin C in Renal Insufficiency Patients Undergoing Cardiac Catheterization

Angiology

Volumn 61, Issue 8, 2010, Pages 724-730

  Ishibashi, Yuki ^a,b   Yamauchi, Masahiro ^b   Musha, Haruki ^b   Mikami, Taishi ^b   Kawasaki, Kensuke ^b   Miyake, Fumihiko ^b  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ST MARIANNA UNIVERSITY   (Japan)

Author keywords

contrast induced nephropathy; coronary catheterization; cystatin C; estimated glomerular filtration rate

Indexed keywords

BIOLOGICAL MARKER; CONTRAST MEDIUM; CREATININE; CYSTATIN C;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEART CATHETERIZATION; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MALE; PATHOPHYSIOLOGY; RADIOGRAPHY; SENSITIVITY AND SPECIFICITY;

AGED; BIOLOGICAL MARKERS; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CREATININE; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HEART CATHETERIZATION; HUMANS; KIDNEY DISEASES; MALE; RENAL INSUFFICIENCY; SENSITIVITY AND SPECIFICITY;

EID: 78049437532     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710379108     Document Type: Article

References (39)

1. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006; 113(14): 1799-1806.
2. Cronin RE. Contrast-induced nephropathy: pathogenesis and prevention. Pediatr Nephrol. 2010; 25(2):191-204.
3. McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med. 2003; 4(suppl 5):S3-S9.
4. Briguori C, Airoldi F, D'Andrea D, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007; 115(10):1211-1217.
5. Ghani AA, Tohamy KY. Risk score for contrast induced nephropathy following percutaneous coronary intervention. Saudi J Kidney Dis Transpl. 2009; 20(2):240-245.
6. McCullough PA, Adam A., Becker CR, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006; 98(6A): 27K-36K.
7. Finn WF. The clinical and renal consequences of contrast-induced nephropathy. Nephrol Dial Transplant. 2006; 21(6):i2-i10.
8. Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int. 2005; 67(2):706-713.
9. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008; 51(15):1419-1428.
10. Mueller-Lenke N, Buerkle G, Klima T, et al. Incidence of contrast-induced nephropathy with volume Suppl.ation-insights from a large cohort. Med Princ Pract. 2008; 17(5):409-414.
11. Kato K, Sato N, Yamamoto T, Iwasaki YK, Tanaka K., Mizuno K. Valuable markers for contrast-induced nephropathy in patients undergoing cardiac catheterization. Circ J. 2008; 72(9):1499-1505.
12. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, et al. NGAL (neutrophil gelatinase-associated lipocalin) and cystatin C: are they good predictors of contrast nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine? Int J Cardiol. 2008; 127(2):290-291.
13. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004; 44(7):1393-1399.
14. Shlipak MG, Ix JH, Bibbins-Domingo K, et al. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. Am J Med. 2008; 121(1):50-57.
15. Benohr P, Grenz A, Hartmann JT, Müller GA, Blaschke S. Cystatin C-a marker for assessment of the glomerular filtration rate in patients with cisplatin chemotherapy. Kidney Blood Press Res. 2006; 29(1):32-35.
16. Fehr T, Rickli H. Reply to Sjostrom et al. Cystatin C and creatinine for assessment of kidney function: differences in pharmacokinetics-and more. Clin Nephrol. 2004; 62(4):327-328.
17. Rickli H, Benou K, Ammann P, et al. Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol. 2004; 61(12):98-102.
18. Imai E. [Equation for estimating GFR from creatinine in Japan]. Nippon Rinsho. 2008; 66(9):1725-1729.
19. Matsuo S. CKD (chronic kidney disease) [in Japanese]. Nippon Jinzo Gakkai Shi. 2007;suppl 50th Ann:67-72.
20. Toprak O. What is the best definition of contrast-induced nephropathy? Ren Fail. 2007; 29(3):387-388.
21. Jabara R, Gadesam RR, Pendyala LK, et al. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention. Am J Cardiol. 2009; 103(12):1657-1662.
22. Solomon RJ, Mehran R, Natarajan MK, et al. Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol. 2009; 4(7):1162-1169.
23. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007; 115(25):3189-3196.
24. Senoo T, Motohiro M, Kamihata H, et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2010; 105(5):624-628.
25. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002; 105(19):2259-2264.
26. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006; 48(4):692-699.
27. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005; 95(1):13-19.
28. Iakovou I, Dangas G, Mehran R, et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol. 2003; 15(1):18-22.
29. Marenzi G. Can contrast-induced nephropathy after percutaneous coronary intervention be accurately predicted with a risk score? Nat Clin Pract Cardiovasc Med. 2005; 2(2):80-81.
30. Shimizu A, Horikoshi S, Rinnno H, Kobata M, Saito K, Tomino Y, et al. Serum cystatin C may predict the early prognostic stages of patients with type 2 diabetic nephropathy. J Clin Lab Anal. 2003; 17(5):164-167.
31. Macisaac RJ, Tsalamandris C, Thomas MC, et al. The accuracy of cystatin C and commonly used creatinine-based methods for detecting moderate and mild chronic kidney disease in diabetes. Diabet Med. 2007; 24(4):443-448.
32. Sato H, Kazama JJ, Kuroda T, Narita I, Nakano M, Gejyo F. Serum cystatin C measured by a sol particle homogeneous immunoassay can accurately detect early impairment of renal function. Clin Exp Nephrol. 2008; 12(4):270-276.
33. Toso A, Maioli M, Leoncini M, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol. 2010; 105(3):288-292.
34. Tamba K, Kusano E, Ando Y, Asano Y. [Prospective evaluation of renal function by serum cystatin-C: comparison with three other parameters of glomerular filtration rate]. Nippon Jinzo Gakkai Shi. 2001; 43(8):646-650.
35. Niccoli G, Conte M, Della Bona R, et al. Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate. Atherosclerosis. 2008; 198(2):373-380.
36. Larsson A, Helmersson J, Hansson LO, Basu S. Serum cystatin C is associated with other cardiovascular risk markers and cardiovascular disease in elderly men. Int J Cardiol. 2008; 125(2):263-264.
37. Shlipak MG, Katz R, Cushman M, et al. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med. 2005; 118(12):1416.
38. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, et al. Could neutrophil-gelatinase-associated lipocalin and cystatin C predict the development of contrast-induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values? Kidney Blood Press Res. 2007; 30(6):408-415.
39. Gambaro G, Graziani MS, Ribichini F. Cystatin C and contrast-induced nephropathy. Nephrol Dial Transplant. 2008; 23(12): 4079-4080.